This article is about a human gene. For Bachelor of Chemical Engineering (BChE) degree, see Bachelor of Engineering.
Butyrylcholinesterase |
PDB rendering based on 1p0i. |
Available structures |
PDB |
Ortholog search: PDBe, RCSB |
List of PDB id codes |
1P0I, 1P0M, 1P0P, 1P0Q, 1XLU, 1XLV, 1XLW, 2J4C, 2PM8, 2WID, 2WIF, 2WIG, 2WIJ, 2WIK, 2WIL, 2WSL, 2XMB, 2XMC, 2XMD, 2XMG, 2XQF, 2XQG, 2XQI, 2XQJ, 2XQK, 2Y1K, 3DJY, 3DKK, 3O9M, 4AQD, 4AXB, 4B0O, 4B0P
|
|
|
Identifiers |
Symbols |
BCHE; CHE1; E1 |
External IDs |
OMIM: 177400 MGI: 894278 HomoloGene: 20065 ChEMBL: 1914 GeneCards: BCHE Gene |
EC number |
3.1.1.8 |
Gene Ontology |
Molecular function |
• beta-amyloid binding
• catalytic activity
• acetylcholinesterase activity
• carboxylesterase activity
• cholinesterase activity
• enzyme binding
• choline binding
|
Cellular component |
• extracellular region
• extracellular space
• nuclear envelope lumen
• endoplasmic reticulum lumen
• membrane
|
Biological process |
• synaptic transmission, cholinergic
• learning
• choline metabolic process
• response to drug
• response to alkaloid
• cocaine metabolic process
• negative regulation of synaptic transmission
• response to glucocorticoid stimulus
• response to folic acid
|
Sources: Amigo / QuickGO |
|
RNA expression pattern |
|
More reference expression data |
Orthologs |
Species |
Human |
Mouse |
|
Entrez |
590 |
12038 |
|
Ensembl |
ENSG00000114200 |
ENSMUSG00000027792 |
|
UniProt |
P06276 |
Q03311 |
|
RefSeq (mRNA) |
NM_000055.2 |
NM_009738.3 |
|
RefSeq (protein) |
NP_000046.1 |
NP_033868.3 |
|
Location (UCSC) |
Chr 3:
165.49 – 165.56 Mb |
Chr 3:
73.64 – 73.71 Mb |
|
PubMed search |
[1] |
[2] |
|
|
Butyrylcholinesterase (also known as pseudocholinesterase, plasma cholinesterase,[1] BCHE, or BuChE) is a non-specific cholinesterase enzyme that hydrolyses many different choline esters. In humans, it is found primarily in the liver[1] and is encoded by the BCHE gene.[2]
It is very similar to the neuronal acetylcholinesterase, which is also known as RBC or erythrocyte cholinesterase.[1] The term "serum cholinesterase" is generally used in reference to a clinical test that reflects levels of both of these enzymes in the blood.[1]
Butyrylcholine is a synthetic compound and does not occur in the body naturally. It is used as a tool to distinguish between acetyl- and butyrylcholinesterase.
Contents
- 1 Clinical significance
- 2 Interactive pathway map
- 3 See also
- 4 References
- 5 Further reading
- 6 External links
|
Clinical significance
Pseudocholinesterase deficiency results in delayed metabolism of only a few compounds of clinical significance, including the following: succinylcholine, mivacurium, procaine, and cocaine. Of these, its most clinically important substrate is the depolarizing neuromuscular blocking agent, succinylcholine, which the pseudocholinesterase enzyme hydrolyzes to succinylmonocholine and then to succinic acid.
In individuals with normal plasma levels of normally functioning pseudocholinesterase enzyme, hydrolysis and inactivation of approximately 90-95% of an intravenous dose of succinylcholine occurs before it reaches the neuromuscular junction. The remaining 5-10% of the succinylcholine dose acts as an acetylcholine receptor agonist at the neuromuscular junction, causing prolonged depolarization of the postsynaptic junction of the motor-end plate. This depolarization initially triggers fasciculation of skeletal muscle. As a result of prolonged depolarization, endogenous acetylcholine released from the presynaptic membrane of the motor neuron does not produce any additional change in membrane potential after binding to its receptor on the myocyte. Flaccid paralysis of skeletal muscles develops within 1 minute. In normal subjects, skeletal muscle function returns to normal approximately 5 minutes after a single bolus injection of succinylcholine as it passively diffuses away from the neuromuscular junction. Pseudocholinesterase deficiency can result in higher levels of intact succinylcholine molecules reaching receptors in the neuromuscular junction, causing the duration of paralytic effect to continue for as long as 8 hours. This condition is recognized clinically when paralysis of the respiratory and other skeletal muscles fails to spontaneously resolve after succinylcholine is administered as an adjunctive paralytic agent during anesthesia procedures. In such cases respiratory assistance is required.[3]
In 2008, an experimental new drug was discovered for the potential treatment of cocaine abuse and overdose based on the pseudocholiesterase structure. It was shown to remove cocaine from the body 2000 times as fast as the natural form of BChE. Studies in rats have shown that the drug prevented convulsions and death when administered cocaine overdoses.[4] This enzyme also metabolizes succinylcholine which accounts for its rapid degradation in the liver and plasma. There may be genetic variability in the kinetics of this enzyme that can lead to prolonged muscle blockade and potentially dangerous respiratory depression that needs to be treated with assisted ventilation.
Mutant alleles at the BCHE locus are responsible for suxamethonium sensitivity. Homozygous persons sustain prolonged apnea after administration of the muscle relaxant suxamethonium in connection with surgical anesthesia. The activity of pseudocholinesterase in the serum is low and its substrate behavior is atypical. In the absence of the relaxant, the homozygote is at no known disadvantage.[5]
Finally, pseudocholinesterase metabolism of procaine results in formation of paraaminobenzoic acid (PABA). If the patient receiving procaine is on sulfonamide antibiotics such as bactrim the antibiotic effect will be antagonized by providing a new source of PABA to the microbe for subsequent synthesis of folic acid.
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. [6]
See also
Cholinesterases
References
- ^ a b c d http://www.umm.edu/ency/article/003358.htm
- ^ Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ (October 1991). "The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26". Genomics 11 (2): 452–4. doi:10.1016/0888-7543(91)90154-7. PMID 1769657.
- ^ emedicine.medscape.com, Pseudocholinesterase deficiency;
- ^ Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D, Tong M, Tai HH, Woods JH, Zhan CG (September 2008). "Most efficient cocaine hydrolase designed by virtual screening of transition states". J. Am. Chem. Soc. 130 (36): 12148–55. doi:10.1021/ja803646t. PMC 2646118. PMID 18710224. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2646118/. Lay summary – ScienceDaily.
- ^ "Entrez Gene: BCHE butyrylcholinesterase". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=590.
- ^ The interactive pathway map can be edited at WikiPathways: "IrinotecanPathway_WP46359". http://www.wikipathways.org/index.php/Pathway:WP46359.
Further reading
- Çokuğraş A. N, Bodur E (2005). "The effects of indole -3-acetic acid on human and horse serum butyrylcholinesterase.". Chemicobiological Interactions 157-158 (16): 375–378. doi:10.1016/j.cbi.2005.10.061. PMID 16429500.
- Lockridge O (1989). "Structure of human serum cholinesterase.". Bioessays 9 (4): 125–8. doi:10.1002/bies.950090406. PMID 3067729.
- Allderdice PW, Gardner HA, Galutira D, et al. (1992). "The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26.". Genomics 11 (2): 452–4. doi:10.1016/0888-7543(91)90154-7. PMID 1769657.
- Gaughan G, Park H, Priddle J, et al. (1992). "Refinement of the localization of human butyrylcholinesterase to chromosome 3q26.1-q26.2 using a PCR-derived probe.". Genomics 11 (2): 455–8. doi:10.1016/0888-7543(91)90155-8. PMID 1769658.
- Arpagaus M, Kott M, Vatsis KP, et al. (1990). "Structure of the gene for human butyrylcholinesterase. Evidence for a single copy.". Biochemistry 29 (1): 124–31. doi:10.1021/bi00453a015. PMID 2322535.
- Nogueira CP, McGuire MC, Graeser C, et al. (1990). "Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG).". Am. J. Hum. Genet. 46 (5): 934–42. PMC 1683584. PMID 2339692. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1683584/.
- McGuire MC, Nogueira CP, Bartels CF, et al. (1989). "Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase.". Proc. Natl. Acad. Sci. U.S.A. 86 (3): 953–7. doi:10.1073/pnas.86.3.953. PMC 286597. PMID 2915989. //www.ncbi.nlm.nih.gov/pmc/articles/PMC286597/.
- Prody CA, Zevin-Sonkin D, Gnatt A, et al. (1987). "Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues.". Proc. Natl. Acad. Sci. U.S.A. 84 (11): 3555–9. doi:10.1073/pnas.84.11.3555. PMC 304913. PMID 3035536. //www.ncbi.nlm.nih.gov/pmc/articles/PMC304913/.
- Lockridge O, Adkins S, La Du BN (1987). "Location of disulfide bonds within the sequence of human serum cholinesterase.". J. Biol. Chem. 262 (27): 12945–52. PMID 3115973.
- McTiernan C, Adkins S, Chatonnet A, et al. (1987). "Brain cDNA clone for human cholinesterase.". Proc. Natl. Acad. Sci. U.S.A. 84 (19): 6682–6. doi:10.1073/pnas.84.19.6682. PMC 299147. PMID 3477799. //www.ncbi.nlm.nih.gov/pmc/articles/PMC299147/.
- Lockridge O, Bartels CF, Vaughan TA, et al. (1987). "Complete amino acid sequence of human serum cholinesterase.". J. Biol. Chem. 262 (2): 549–57. PMID 3542989.
- Jbilo O, Toutant JP, Vatsis KP, et al. (1994). "Promoter and transcription start site of human and rabbit butyrylcholinesterase genes.". J. Biol. Chem. 269 (33): 20829–37. PMID 8063698.
- Mattes C, Bradley R, Slaughter E, Browne S (1996). "Cocaine and butyrylcholinesterase (BChE): determination of enzymatic parameters.". Life Sci. 58 (13): PL257–61. doi:10.1016/0024-3205(96)00065-3. PMID 8622553.
- Iida S, Kinoshita M, Fujii H, et al. (1996). "Mutations of human butyrylcholinesterase gene in a family with hypocholinesterasemia.". Hum. Mutat. 6 (4): 349–51. doi:10.1002/humu.1380060411. PMID 8680411.
- Kamendulis LM, Brzezinski MR, Pindel EV, et al. (1996). "Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases.". J. Pharmacol. Exp. Ther. 279 (2): 713–7. PMID 8930175.
- Hidaka K, Iuchi I, Tomita M, et al. (1998). "Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency.". Ann. Hum. Genet. 61 (Pt 6): 491–6. doi:10.1046/j.1469-1809.1997.6160491.x. PMID 9543549.
- Browne SP, Slaughter EA, Couch RA, et al. (1998). "The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma.". Biopharmaceutics & drug disposition 19 (5): 309–14. doi:10.1002/(SICI)1099-081X(199807)19:5<309::AID-BDD108>3.0.CO;2-9. PMID 9673783.
- Altamirano CV, Lockridge O (1999). "Conserved aromatic residues of the C-terminus of human butyrylcholinesterase mediate the association of tetramers.". Biochemistry 38 (40): 13414–22. doi:10.1021/bi991475. PMID 10529218.
- Darvesh S, Kumar R, Roberts S, et al. (2002). "Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin.". Cell. Mol. Neurobiol. 21 (3): 285–96. doi:10.1023/A:1010947205224. PMID 11569538.
- Barta C, Sasvari-Szekely M, Devai A, et al. (2002). "Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia.". Mol. Genet. Metab. 74 (4): 484–8. doi:10.1006/mgme.2001.3251. PMID 11749053.
External links
- Butyrylcholinesterase at the US National Library of Medicine Medical Subject Headings (MeSH)
PDB gallery
|
|
|
1p0i: Crystal structure of human butyryl cholinesterase
|
|
1p0m: Crystal structure of human butyryl cholinesterase in complex with a choline molecule
|
|
1p0p: Crystal structure of soman-aged human butyryl cholinesterase in complex with the substrate analog butyrylthiocholine
|
|
1p0q: Crystal structure of soman-aged human butyryl cholinesterase
|
|
1xlu: X-Ray Structure Of Di-Isopropyl-Phosphoro-Fluoridate (Dfp) Inhibited Butyrylcholinesterase after Aging
|
|
1xlv: Ethylphosphorylated Butyrylcholinesterase (Aged) Obtained By Reaction With Echothiophate
|
|
1xlw: Diethylphosphorylated Butyrylcholinesterase (Nonaged) Obtained By Reaction With Echothiophate
|
|
2j4c: STRUCTURE OF HUMAN BUTYRYLCHOLINESTERASE IN COMPLEX WITH 10MM HGCL2
|
|
|
|
Hydrolase: esterases (EC 3.1)
|
|
3.1.1: Carboxylic ester hydrolases |
- Cholinesterase
- Acetylcholinesterase
- Butyrylcholinesterase
- Pectinesterase
- 6-phosphogluconolactonase
- PAF acetylhydrolase
- Lipase
- Bile salt-dependent
- Gastric/Lingual
- Pancreatic
- Lysosomal
- Hormone-sensitive
- Endothelial
- Hepatic
- Lipoprotein
- Monoacylglycerol
- Diacylglycerol
|
|
3.1.2: Thioesterase |
- Palmitoyl protein thioesterase
- Ubiquitin carboxy-terminal hydrolase L1
|
|
3.1.3: Phosphatase |
- Alkaline phosphatase
- Acid phosphatase (Prostatic)/Tartrate-resistant acid phosphatase/Purple acid phosphatases
- Nucleotidase
- Glucose 6-phosphatase
- Fructose 1,6-bisphosphatase
- Phosphoprotein phosphatase
- OCRL
- Pyruvate dehydrogenase phosphatase
- Fructose 6-P,2-kinase:fructose 2,6-bisphosphatase
- PTEN
- Phytase
- Inositol-phosphate phosphatase
- Phosphoprotein phosphatase: Protein tyrosine phosphatase
- Protein serine/threonine phosphatase
- Dual-specificity phosphatase
|
|
3.1.4: Phosphodiesterase |
- Autotaxin
- Phospholipase
- Sphingomyelin phosphodiesterase
- PDE1
- PDE2
- PDE3
- PDE4A/PDE4B
- PDE5
- Lecithinase (Clostridium perfringens alpha toxin)
- Cyclic nucleotide phosphodiesterase
|
|
3.1.6: Sulfatase |
- arylsulfatase
- Arylsulfatase A
- Arylsulfatase B
- Arylsulfatase E
- Steroid sulfatase
- Galactosamine-6 sulfatase
- Iduronate-2-sulfatase
- N-acetylglucosamine-6-sulfatase
|
|
Nuclease (includes
deoxyribonuclease and
ribonuclease) |
3.1.11-16: Exonuclease |
Exodeoxyribonuclease |
|
|
Exoribonuclease |
|
|
|
3.1.21-31: Endonuclease |
Endodeoxyribonuclease |
- Deoxyribonuclease I
- Deoxyribonuclease II
- Deoxyribonuclease IV
- Restriction enzyme
- UvrABC endonuclease
|
|
Endoribonuclease |
- RNase III
- RNase H
- RNase P
- RNase A
- RNase T1
- RNA-induced silencing complex
|
|
either deoxy- or ribo- |
- Aspergillus nuclease S1
- Micrococcal nuclease
|
|
|
|
- B
- enzm
- 1.1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 10
- 11
- 13
- 14
- 15-18
- 2.1
- 2.7.10
- 2.7.11-12
- 3.1
- 4.1
- 5.1
- 6.1-3
|
|
|
|
Metabolism: amino acid metabolism · neurotransmitter enzymes
|
|
monoamine |
histidine→histamine
|
anabolism: Histidine decarboxylase
catabolism: Histamine N-methyltransferase · Amine oxidase
|
|
tyrosine→dopamine→epinephrine
|
anabolism: Tyrosine hydroxylase · Aromatic L-amino acid decarboxylase · Dopamine beta hydroxylase · Phenylethanolamine N-methyltransferase
catabolism: Catechol-O-methyl transferase · Monoamine oxidase
|
|
glutamate→GABA
|
anabolism: Glutamate decarboxylase
catabolism: 4-aminobutyrate transaminase
|
|
tryptophan→serotonin→melatonin
|
Tryptophan hydroxylase · Aromatic L-amino acid decarboxylase · Acetylserotonin O-methyltransferase
|
|
|
arginine→NO |
Nitric oxide synthase (NOS1, NOS2, NOS3)
|
|
choline→Acetylcholine |
anabolism: Choline acetyltransferase
catabolism: Cholinesterase (Acetylcholinesterase, Butyrylcholinesterase)
|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
|
|
Cholinergics
|
|
Receptor ligands
|
|
mAChR
|
- Agonists: 77-LH-28-1
- AC-42
- AC-260,584
- Aceclidine
- Acetylcholine
- AF30
- AF150(S)
- AF267B
- AFDX-384
- Alvameline
- AQRA-741
- Arecoline
- Bethanechol
- Butyrylcholine
- Carbachol
- CDD-0034
- CDD-0078
- CDD-0097
- CDD-0098
- CDD-0102
- Cevimeline
- Choline
- cis-Dioxolane
- Ethoxysebacylcholine
- LY-593,039
- L-689,660
- LY-2,033,298
- McNA343
- Methacholine
- Milameline
- Muscarine
- NGX-267
- Ocvimeline
- Oxotremorine
- PD-151,832
- Pilocarpine
- RS86
- Sabcomeline
- SDZ 210-086
- Sebacylcholine
- Suberylcholine
- Talsaclidine
- Tazomeline
- Thiopilocarpine
- Vedaclidine
- VU-0029767
- VU-0090157
- VU-0152099
- VU-0152100
- VU-0238429
- WAY-132,983
- Xanomeline
- YM-796
Antagonists: 3-Quinuclidinyl Benzilate
- 4-DAMP
- Aclidinium Bromide
- Anisodamine
- Anisodine
- Atropine
- Atropine Methonitrate
- Benactyzine
- Benzatropine/Benztropine
- Benzydamine
- BIBN 99
- Biperiden
- Bornaprine
- CAR-226,086
- CAR-301,060
- CAR-302,196
- CAR-302,282
- CAR-302,368
- CAR-302,537
- CAR-302,668
- CS-27349
- Cyclobenzaprine
- Cyclopentolate
- Darifenacin
- DAU-5884
- Dimethindene
- Dexetimide
- DIBD
- Dicyclomine/Dicycloverine
- Ditran
- EA-3167
- EA-3443
- EA-3580
- EA-3834
- Etanautine
- Etybenzatropine/Ethylbenztropine
- Flavoxate
- Himbacine
- HL-031,120
- Ipratropium bromide
- J-104,129
- Hyoscyamine
- Mamba Toxin 3
- Mamba Toxin 7
- Mazaticol
- Mebeverine
- Methoctramine
- Metixene
- N-Ethyl-3-Piperidyl Benzilate
- N-Methyl-3-Piperidyl Benzilate
- Orphenadrine
- Otenzepad
- Oxybutynin
- PBID
- PD-102,807
- PD-0298029
- Phenglutarimide
- Phenyltoloxamine
- Pirenzepine
- Piroheptine
- Procyclidine
- Profenamine
- RU-47,213
- SCH-57,790
- SCH-72,788
- SCH-217,443
- Scopolamine/Hyoscine
- Solifenacin
- Telenzepine
- Tiotropium bromide
- Tolterodine
- Trihexyphenidyl
- Tripitamine
- Tropatepine
- Tropicamide
- WIN-2299
- Xanomeline
- Zamifenacin; Others: 1st Generation Antihistamines (Brompheniramine
- chlorphenamine
- cyproheptadine
- dimenhydrinate
- diphenhydramine
- doxylamine
- mepyramine/pyrilamine
- phenindamine
- pheniramine
- tripelennamine
- triprolidine, etc)
- Tricyclic Antidepressants (Amitriptyline
- doxepin
- trimipramine, etc)
- Tetracyclic Antidepressants (Amoxapine
- maprotiline, etc)
- Typical Antipsychotics (Chlorpromazine
- thioridazine, etc)
- Atypical Antipsychotics (Clozapine
- olanzapine
- quetiapine, etc)
|
|
nAChR
|
- Agonists: 5-HIAA
- A-84,543
- A-366,833
- A-582,941
- A-867,744
- ABT-202
- ABT-418
- ABT-560
- ABT-894
- Acetylcholine
- Altinicline
- Anabasine
- Anatoxin-a
- AR-R17779
- Butinoline
- Butyrylcholine
- Carbachol
- Choline
- Cotinine
- Cytisine
- Decamethonium
- Desformylflustrabromine
- Dianicline
- Dimethylphenylpiperazinium
- Epibatidine
- Epiboxidine
- Ethanol
- Ethoxysebacylcholine
- EVP-4473
- EVP-6124
- Galantamine
- GTS-21
- Ispronicline
- Lobeline
- MEM-63,908/RG-3487
- Nicotine
- NS-1738
- PHA-543,613
- PHA-709,829
- PNU-120,596
- PNU-282,987
- Pozanicline
- Rivanicline
- RJR-2429
- Sazetidine A
- Sebacylcholine
- SIB-1508Y
- SIB-1553A
- SSR-180,711
- Suberylcholine
- Suxamethonium/Succinylcholine
- TC-1698
- TC-1734
- TC-1827
- TC-2216
- TC-5214
- TC-5619
- TC-6683
- Tebanicline
- Tropisetron
- UB-165
- Varenicline
- WAY-317,538
- XY-4083
Antagonists: 18-Methoxycoronaridine
- α-Bungarotoxin
- α-Conotoxin
- Alcuronium
- Amantadine
- Anatruxonium
- Atracurium
- Bupropion
- Chandonium
- Chlorisondamine
- Cisatracurium
- Coclaurine
- Coronaridine
- Dacuronium
- Decamethonium
- Dextromethorphan
- Dextropropoxyphene
- Dextrorphan
- Diadonium
- DHβE
- Dimethyltubocurarine/Metocurine
- Dipyrandium
- Dizocilpine/MK-801
- Doxacurium
- Duador
- Esketamine
- Fazadinium
- Gallamine
- Hexafluronium
- Hexamethonium/Benzohexonium
- Ibogaine
- Isoflurane
- Ketamine
- Kynurenic acid
- Laudexium/Laudolissin
- Levacetylmethadol
- Malouetine
- Mecamylamine
- Memantine
- Methadone (Levomethadone)
- Methorphan/Racemethorphan
- Methyllycaconitine
- Metocurine
- Mivacurium
- Morphanol/Racemorphan
- Neramexane
- Nitrous Oxide
- Pancuronium
- Pempidine
- Pentamine
- Pentolinium
- Phencyclidine
- Pipecuronium
- Radafaxine
- Rapacuronium
- Rocuronium
- Surugatoxin
- Thiocolchicoside
- Toxiferine
- Trimethaphan
- Tropeinium
- Tubocurarine
- Vecuronium
- Xenon
|
|
|
|
Reuptake inhibitors
|
|
Plasmalemmal
|
CHT Inhibitors
|
- Hemicholinium-3/Hemicholine
- Triethylcholine
|
|
|
Vesicular
|
|
|
|
|
Enzyme inhibitors
|
|
Anabolism
|
ChAT inhibitors
|
- 1-(-Benzoylethyl)pyridinium
- 2-(α-Naphthoyl)ethyltrimethylammonium
- 3-Chloro-4-stillbazole
- 4-(1-Naphthylvinyl)pyridine
- Acetylseco hemicholinium-3
- Acryloylcholine
- AF64A
- B115
- BETA
- CM-54,903
- N,N-Dimethylaminoethylacrylate
- N,N-Dimethylaminoethylchloroacetate
|
|
|
Catabolism
|
AChE inhibitors
|
|
|
BChE inhibitors
|
- Cymserine * Many of the acetylcholinesterase inhibitors listed above act as butyrylcholinesterase inhibitors.
|
|
|
|
|
Others
|
|
Precursors
|
- Choline (Lecithin)
- Citicoline
- Cyprodenate
- Dimethylethanolamine
- Glycerophosphocholine
- Meclofenoxate/Centrophenoxine
- Phosphatidylcholine
- Phosphatidylethanolamine
- Phosphorylcholine
- Pirisudanol
|
|
Cofactors
|
- Acetic acid
- Acetylcarnitine
- Acetyl-coA
- Vitamin B5 (Pantethine
- Pantetheine
- Panthenol)
|
|
Others
|
- Acetylcholine releasing agents: α-Latrotoxin
- β-Bungarotoxin; Acetylcholine release inhibitors: Botulinum toxin (Botox); Acetylcholinesterase reactivators: Asoxime
- Obidoxime
- Pralidoxime
|
|
|
|